PMI appoints Matthew Holman as Vice President of Regulatory Strategy

Sep.20.2022
PMI appoints Matthew Holman as Vice President of Regulatory Strategy
Matthew Holman leaves FDA role to become PMI's US Science Engagement and Regulatory Strategy VP as the company seeks to promote safer nicotine alternatives.

Matthew Holman has left his position at the FDA to become the Vice President of Scientific Engagement and Regulatory Strategy for PMI in the United States.


Of course, considering the tobacco companies are currently facing strict regulations and public scrutiny, these appointments are crucial. Badrul Chowdhury, who has worked at the FDA for over 20 years, has accepted the position of Chief Life Sciences Officer, while Matthew Holman has been appointed as Vice President of Science Engagement and Regulatory Strategy for the tobacco company in the United States.


In recent years, Philip Morris International (PMI) has been making efforts to improve its image and reputation by turning towards the sale of safer nicotine alternatives. Former CEO Andre Catantzopoulos believed that a smokeless future is possible and that achieving a consensus with the government and society is necessary through proper supervision and regulation. He stated that alternative nicotine products can be a part of effective tobacco policy. "Thanks to rapid progress in science and technology, and PMI's firm commitment, these products have now become a reality," he said.


Although current CEO of PMI, Jacek Olczak, has stated that the tobacco company intends to achieve its goal of 50% smoke-free product sales by 2025, he also claims the company is fully capable of replacing cigarettes with safer alternatives. "We have a leading portfolio of traditional and smoke-free tobacco products, an excellent management team, and an agile, efficient, and quick-learning organization. We are fully capable of continuing to succeed in our vision of replacing cigarettes with better alternatives for the benefit of consumers, shareholders, and society," he stated earlier this year, quoted by The Edge.


PMI is working hard to change its image.


Last year, PMI received criticism from the British Asthma Association and British Lung Foundation for their collaboration with asthma inhaler manufacturer Vectura. This move appeared hypocritical, as the investment was in a product that could help treat tobacco-related diseases.


Meanwhile, Altria has recently reiterated its plan to enter the healthcare field, stating that this is a natural evolution for tobacco companies. "This is a natural evolution for PMI to further transform our business into a more holistic lifestyle, consumer health, and healthcare company in the future. This evolution is not only fulfilling our continued commitment to a smoke-free future but also fulfilling the development and commercialization of scientifically validated products and solutions to meet unmet consumer and patient needs.


The market for health and wellness products is vast and constantly expanding. We have several key areas of focus in our pipeline. For consumers and over-the-counter healthcare products, we have several initiatives focused on concentration, sleep, energy, pain relief, and calmness. In the healthcare field, we believe that patients' demand for fast and effective treatments for cardiovascular diseases such as myocardial infarction and neurological conditions such as migraines has yet to be met, and innovative solutions can meet these needs. We recently accelerated this part of our strategy through the acquisition of Vectura, an innovative inhalation delivery solution provider, and Fertin, a leading developer and manufacturer of innovative drugs and healthcare products based on oral and intraoral delivery systems," said Alzack.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is solely for communication and research within the industry.


Due to limitations in translation abilities, the translated article may not fully express the original text, so please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any statements or positions relating to domestic issues, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
Product | KT&G Launches lil HYBRID 3.0 Misty Rosé Edition II in South Korea With Two Pink Finishes at 88,000 Won
South Korean tobacco company KT&G launched the limited-edition lil HYBRID 3.0 Misty Rosé Edition II on September 30, 2026, following the original Misty Rosé Edition introduced in November 2025. The new release comes in two pink finishes, Bloom Rosé and Viva Rosé, each priced at 88,000 won. Both versions initially went on sale through the lil Store online shop and lil MINIMALIUM flagship stores. From October 7, Bloom Rosé became available at approximately 1,500 lil Station retail outlets nationwide. The release retains the existing lil HYBRID 3.0 hybrid heated tobacco platform, with changes focused on exterior design and distribution.
product
Oct.10
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
China's Ministry of Finance and State Taxation Administration announced on October 12, 2026, that value-added tax (VAT) export rebates for vape devices, nicotine and its salts, and certain non-combustible inhalation products will be eliminated from April 1, 2027. The measure adds four tobacco- and nicotine-related customs codes, including 8543400010, which covers vape devices and qualifying empty pods. China previously eliminated rebates for nicotine-containing vaping products and devices under code 8543400090 in April 2026. According to industry classification information held by 2Firsts, the latter currently corresponds to heated tobacco devices. Export excise tax refund and exemption arrangements will remain unchanged.
Special Report
Oct.12
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10